A detailed history of Independent Advisor Alliance transactions in Altimmune, Inc. stock. As of the latest transaction made, Independent Advisor Alliance holds 21,200 shares of ALT stock, worth $142,888. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21,200
Previous 22,000 3.64%
Holding current value
$142,888
Previous $223,000 37.22%
% of portfolio
0.0%
Previous 0.01%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$5.91 - $10.23 $4,728 - $8,184
-800 Reduced 3.64%
21,200 $140,000
Q1 2024

May 08, 2024

BUY
$8.22 - $13.81 $98,640 - $165,720
12,000 Added 120.0%
22,000 $223,000
Q4 2023

Feb 08, 2024

BUY
$2.14 - $11.62 $21,400 - $116,199
10,000 New
10,000 $112,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $330M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Independent Advisor Alliance Portfolio

Follow Independent Advisor Alliance and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Independent Advisor Alliance, based on Form 13F filings with the SEC.

News

Stay updated on Independent Advisor Alliance with notifications on news.